English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Antibiotic resistance among gram-negative bacilli shows no signs of abatement. Resistance of Pseudomonas aeruginosa, Acinetobacter baumannii, and the Enterobacteriaceae to multiple antibiotic classes is a growing clinical problem worldwide [1]. Two trends are particularly noteworthy. First, there has been increased recognition of successful antibiotic-resistant clones appearing in multiple geographic regions. Multilocus sequence typing analyses of contemporary collections of multidrug-resistant strains have shown that carbapenem-resistant A. baumannii ST92 [2], K. pneumoniae carbapenemase–producing K. pneumoniae ST258 [3], and extended-spectrum b-lactamase–producing Escherichia coli ST131 [4] are global problems. Second, new mechanisms of multidrug resistance are becoming evident. These include aminoglycoside 16S ribosomal RNA methylation [5] and production of the New Delhi metallo-b-lactamase [6].

How Soon Is Now? The Urgent Need for Randomized, Controlled Trials Evaluating Treatment of Multidrug‐Resistant Bacterial Infection